Prostate cancer

You are here

Towards a world without prostate cancer

To successfully cure patients with prostate cancer it is important to detect the disease at an early stage. Current screening techniques are based on a measurement of serum prostate specific antigen (PSA) levels and a digital rectal examination (DRE). Drawbacks of PSA testing are its low sensitivity and specificity. Recently, prostate cancer specific markers for the early detection of disease and the prediction of aggressiveness of a prostate tumor have become available. 

[“Prostate cancer is the most frequently
diagnosed cancer and the second leading cause
of death among men in Western countries”]

First-void is an innovative approach to non-invasive prostate cancer testing

Because of the ease of collection and the fact that prostate cells are directly released into the urethra through prostatic ducts after DRE or prostate massage, urine has become the future of non-invasive biomarker testing.¹ 

Many studies have shown the feasibility of urine for the non-invasive detection of PCa.¹ In 2008, Theodorescu et al. found that midstream urine was uninformative, but first-void urine was able to identify patients with prostate cancer with 91% sensitivity and 69% specificity.²

“It is well-timed that our UrNCollect device is launched as
a complement to the SelectMDx IVD PCR kit because
pilot studies demonstrated that patients and physicians
found the device easier to use than traditional urine
collection tubes.” Dr Jan Groen, CEO MDxHealth

1. Hessels & Schalken, 2013 2. Theodorescu et al., 2008